Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide added to metformin with or without basal insulin in pediatric type 2 diabetes
NL-OMON43231Phase 3Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Jun 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Liraglutide + metformin with or without basal insulin with Placebo + metformin with or without basal insulin (2 arms). Primary endpoint: Change in HbA1c from baseline to week 26. Planned start Jun 2016; status: withdrawn.
02
Drugs
liraglutidemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON43231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43231.